GRCL Stock Recent News

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative and highly efficacious cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three upcoming investor conferences.

Gracell Biotechnologies Inc. Sponsored ADR (GRCL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative and highly efficacious cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at two upcoming investor conferences.

Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants William Cao - Chairman, Chief Executive Officer Wendy Li - Chief Medical Officer Kevin Xie - Chief Financial Officer Conference Call Participants Kelly Shi - Jefferies Joe Cantanzaro - Piper Sadler Justin Zelin - BTIG Emily Bodnar - Wainwright Yigal Nochomovitz - Citigroup Operator Ladies and gentlemen, thank you for standing by. My name is Bhavesh, and I'll be your conference operator today.

Gracell Biotechnologies is a clinical-stage biotech company based in China. The company's lead therapy is in four different trials to treat various diseases.

SAN DIEGO and SUZHOU, China and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the second quarter ended June 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, August 14, 2023. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.

Shares of Gracell (GRCL) increase after it reported positive data from two clinical studies, which evaluated its experimental CAR T cell therapy drug in patients with B-cell non-hodgkin's lymphoma and multiple myeloma.

Two analysts upgraded their ratings for Gracell Biotechnologies' stock. Over the weekend, Gracell announced positive follow-up trial data regarding its lead therapy.

First disclosure of data from Phase 1 study of the donor-derived allogeneic CAR-T GC007g shows 100% overall response rate (ORR) and a favorable safety profile for treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) Longer-term GC012F data in relapsed/refractory multiple myeloma (RRMM) and B-cell non-Hodgkin's lymphoma (B-NHL) indications to be highlighted, with B-NHL data selected for oral presentation   SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , May 11, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that clinical data from three studies in B-NHL, RRMM and B-ALL will be presented at the 2023 European Hematology Association (EHA) Annual Meeting taking place June 8-15 in Frankfurt, Germany, and online.

SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 10, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at two upcoming in-person investor conferences.